Zahid Kocak, M. (2021). Comment on ‘Impact of performance status on non-small cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab’. Acta Oncologica, 60(4), 564–565. https://doi.org/10.1080/0284186X.2021.1889028